GRAIL Securities Fraud Class Action

Illumina — Holy Grail, Inc., a commercial-stage healthcare company focused on early cancer detection, is facing multiple securities fraud class action lawsuits filed by numerous law firms on behalf of investors who purchased Illumina — Holy Grail common stock between May 13, 2025 and February 19, 2026. The lawsuits allege that Illumina — Holy Grail and certain of its officers made materially false and misleading statements regarding the NHS-Galleri trial, a large-scale cancer screening study conducted with the UK's United Kingdom — National Health Service. Specifically, the complaints claim that Illumina — Holy Grail overstated the likelihood of achieving the trial's primary endpoint of a statistically significant reduction in Stage III-IV cancers, concealed adverse data trends, and misrepresented the adequacy of the three-year follow-up period. On February 19, 2026, Illumina — Holy Grail announced that the trial did not meet its primary endpoint, attributing the shortcoming partly to the need for a longer follow-up period. This disclosure caused Illumina — Holy Grail's stock price to plummet by 50.55% in a single day, from $101.53 to $50.21 per share, erasing over $2.2 billion in market capitalization. The class action lawsuits, filed in the U.S. District Court for the Northern District of California, seek to recover damages for investors. The lead plaintiff deadline is August 4, 2026.